Jun 16, 2020
CAR-T Therapy Market Outlook to 2030 by Target Antigen, Application, Region, Country and Company
Apr 22, 2020
Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Apr 17, 2020
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma | US & EU Market Sizes from 2017 to 2030, Details of Marketed & Emerging Therapies Kymriah (Novartis) & KTE-X19 (Gilead Sciences)
Feb 19, 2020
New study finds cellular immunotherapy treatment associated with improved quality of life
Jun 26, 2019
Kymriah (tisagenlecleucel; Novartis) Drug Profile 2019: A Cluster of Differentiation (CD)19-Targeted Genetically Modified Autologous T-cell Immunotherapy
Dec 03, 2018
CAR T-Cell Therapies Show Durable Responses, New Research Also Explores Combination Therapies to Extend and Enhance Treatment Responses
Dec 01, 2018
Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
Oct 29, 2018
Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®
Aug 27, 2018
Pioneers at Children's Hospital of Philadelphia Greet European Commission's Approval of Kymriah as Landmark Medical Advance for Young Cancer Patients in Europe
Jul 30, 2018
Current Research & Developments Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy
Jun 16, 2018
Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL
Jun 14, 2018
Global CAR T Cell Therapy Market 2016-2026: The Most Hot Topic Discussed Among Oncologists Throughout the Globe
May 17, 2018
Novartis data at ASCO and EHA reinforce company's commitment to reimagining cancer
May 02, 2018
More Progress on LLS-Supported CAR T-cell Immunotherapy, A Revolutionary Approach to Cancer Treatment
May 01, 2018
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
Feb 13, 2018
Pioneering immunotherapy to find and kill elusive cancer cells in children at Lucile Packard Children's Hospital Stanford
Jan 31, 2018
Novartis Announces NEJM Publication Of Updated Analysis From ELIANA Trial Showing Longer-Term Durable Remissions With Kymriah(TM) In Children, Young Adults With r/r ALL
Jan 31, 2018
T Cell Therapy Shows Persistent Benefits in Young Leukemia Patients
Jan 17, 2018
Technology Advancements to Conquer the Precision Medicine Market
Jan 17, 2018
Novartis granted US FDA Priority Review for Kymriah(TM) (tisagenlecleucel), formerly CTL019, for adults with r/r DLBCL